

# Giovanni Raimondo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8671243/publications.pdf>

Version: 2024-02-01

54  
papers

4,431  
citations

257450  
24  
h-index

168389  
53  
g-index

54  
all docs

54  
docs citations

54  
times ranked

4194  
citing authors

#	ARTICLE	IF	CITATIONS
1	Occult Hepatitis B Virus Infection in Patients with Chronic Hepatitis C Liver Disease. New England Journal of Medicine, 1999, 341, 22-26.	27.0	651
2	Control of cccDNA function in hepatitis B virus infection. Journal of Hepatology, 2009, 51, 581-592.	3.7	476
3	Occult hepatitis B virus infection. Journal of Hepatology, 2007, 46, 160-170.	3.7	458
4	Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology, 2004, 126, 102-110.	1.3	389
5	Update of the statements on biology and clinical impact of occult hepatitis B virus infection. Journal of Hepatology, 2019, 71, 397-408.	3.7	341
6	Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. Gastroenterology, 2018, 155, 411-421.e4.	1.3	291
7	Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology, 2006, 43, 100-107.	7.3	191
8	Occult HBV infection. Seminars in Immunopathology, 2013, 35, 39-52.	6.1	190
9	Occult hepatitis B virus in liver tissue of individuals without hepatic disease. Journal of Hepatology, 2008, 48, 743-746.	3.7	171
10	Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. Journal of Hepatology, 2019, 71, 265-273.	3.7	138
11	Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer, 2006, 106, 1326-1330.	4.1	118
12	Occult hepatitis B infection and hepatocellular carcinoma: Epidemiology, virology, hepatocarcinogenesis and clinical significance. Journal of Hepatology, 2020, 73, 952-964.	3.7	115
13	Hepatitis B virus (<scp>HBV</scp>) <scp>DNA</scp> integration in patients with occult <scp>HBV</scp> infection and hepatocellular carcinoma. Liver International, 2015, 35, 2311-2317.	3.9	92
14	Impact of occult hepatitis B virus infection on the outcome of chronic hepatitis C. Journal of Hepatology, 2013, 59, 696-700.	3.7	88
15	The changing scenario of hepatocellular carcinoma in Italy: an update. Liver International, 2021, 41, 585-597.	3.9	69
16	Obesity and liver cancer. Annals of Hepatology, 2019, 18, 810-815.	1.5	58
17	Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002â€“2033: the ITA.LI.CA database. Gut, 2023, 72, 141-152.	12.1	57
18	Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients. Antiviral Therapy, 2009, 14, 649-654.	1.0	53

#	ARTICLE	IF	CITATIONS
19	What is the clinical impact of occult hepatitis B virus infection?. <i>Lancet</i> , The, 2005, 365, 638-640.	13.7	52
20	Interferon- $\alpha$ therapy May induce insulin autoantibody development in patients with chronic viral hepatitis. <i>Digestive Diseases and Sciences</i> , 1996, 41, 1672-1677.	2.3	49
21	Occult hepatitis B virus and the risk for chronic liver disease: A meta-analysis. <i>Digestive and Liver Disease</i> , 2013, 45, 238-244.	0.9	46
22	Is Transient Elastography Needed for Noninvasive Assessment of High-Risk Varices? The REAL Experience. <i>American Journal of Gastroenterology</i> , 2019, 114, 1275-1282.	0.4	41
23	Virological Profiles in Hepatitis B Virus/Hepatitis C Virus Coinfected Patients under Interferon plus Ribavirin Therapy. <i>Antiviral Therapy</i> , 2006, 11, 931-934.	1.0	29
24	Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?. <i>Journal of Hepatology</i> , 2018, 68, 597-600.	3.7	28
25	Occult Hepatitis B Virus Infection: An Update. <i>Viruses</i> , 2022, 14, 1504.	3.3	22
26	Pattern of macrovascular invasion in hepatocellular carcinoma. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13542.	3.4	18
27	Erectile dysfunction in compensated liver cirrhosis. <i>Digestive and Liver Disease</i> , 2019, 51, 843-849.	0.9	17
28	Resistance analysis and treatment outcomes in hepatitis C virus genotype 3a-infected patients within the Italian network VIRONET-EC. <i>Liver International</i> , 2021, 41, 1802-1814.	3.9	12
29	Human Hepatitis B Virus Negatively Impacts the Protective Immune Crosstalk Between Natural Killer and Dendritic Cells. <i>Hepatology</i> , 2021, 74, 550-565.	7.3	12
30	Occult hepatitis B virus infection predicts nonalcoholic steatohepatitis in severely obese individuals from Italy. <i>Liver International</i> , 2020, 40, 1601-1609.	3.9	11
31	Elective endoscopic variceal ligation is not a risk factor for bacterial infection in patients with liver cirrhosis. <i>Digestive and Liver Disease</i> , 2018, 50, 366-369.	0.9	10
32	Flavocoxid exerts a potent antiviral effect against hepatitis B virus. <i>Inflammation Research</i> , 2018, 67, 89-103.	4.0	10
33	Monofocal hepatocellular carcinoma: How much does size matter?. <i>Liver International</i> , 2021, 41, 396-407.	3.9	10
34	Hepatitis B virus and hepatitis C virus co-infection: additive players in chronic liver disease?. <i>Annals of Hepatology</i> , 2005, 4, 100-6.	1.5	10
35	Hypergammaglobulinemia is a strong predictor of disease progression, hepatocellular carcinoma, and death in patients with compensated cirrhosis. <i>Liver International</i> , 2018, 38, 1220-1229.	3.9	9
36	Outcome of cutaneous psoriasis in hepatitis C virus-infected patients treated with Direct-Acting Antiviral therapy. <i>Journal of Viral Hepatitis</i> , 2020, 27, 333-337.	2.0	9

#	ARTICLE	IF	CITATIONS
37	Surveillance as Determinant of Long-Term Survival in Non-Transplanted Hepatocellular Carcinoma Patients. <i>Cancers</i> , 2021, 13, 897.	3.7	9
38	Over time evaluation of glycaemic control in direct-acting antiviral-treated hepatitis C virus/diabetic individuals with chronic hepatitis or with cirrhosis. <i>Liver International</i> , 2021, 41, 2059-2067.	3.9	9
39	Changes in hepatocellular carcinoma aggressiveness characteristics with an increase in tumor diameter. <i>International Journal of Biological Markers</i> , 2021, 36, 54-61.	1.8	8
40	Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study.. <i>Digestive and Liver Disease</i> , 2021, 53, 1011-1019.	0.9	7
41	Evaluation of CTNNB1 and TP53 variability in patients with hepatocellular carcinoma and occult hepatitis B virus infection. <i>Cancer Genetics</i> , 2015, 208, 513-516.	0.4	6
42	Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Liver Cancer</i> , 2021, 10, 126-136.	7.7	6
43	A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study. <i>Cancers</i> , 2021, 13, 2677.	3.7	6
44	Free episomal and integrated HBV DNA in HBsAg-negative patients with intrahepatic cholangiocarcinoma. <i>Oncotarget</i> , 2019, 10, 3931-3938.	1.8	6
45	Identification of Clinical Phenotypes and Related Survival in Patients with Large HCCs. <i>Cancers</i> , 2021, 13, 592.	3.7	5
46	Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment. <i>Frontiers in Oncology</i> , 2022, 12, 822507.	2.8	5
47	Occult hepatitis B virus infection in hepatitis C virus negative chronic liver diseases. <i>Liver International</i> , 2022, 42, 963-972.	3.9	5
48	Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survival. <i>Digestive and Liver Disease</i> , 2022, 54, 927-936.	0.9	4
49	Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment. <i>European Journal of Cancer</i> , 2021, 158, 133-143.	2.8	4
50	Antibody to hepatitis B virus core antigen positivity is a predictor of non-alcoholic fatty liver disease severity. <i>Internal and Emergency Medicine</i> , 2022, 17, 1609-1616.	2.0	3
51	Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2022, 54, 1215-1221.	0.9	3
52	Recalibrating survival prediction among patients receiving transarterial chemoembolization for hepatocellular carcinoma. <i>Liver Cancer International</i> , 2021, 2, 45-53.	1.3	2
53	Ficolin-2 Plasma Level Assesses Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2813.	4.1	2
54	Prevalence of hepatitis B and C viral infections in hospitalized patients with increased liver enzyme levels and with no known history of hepatic disease. <i>Annals of Hepatology</i> , 2021, , 100578.	1.5	0